UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extension of in vivo half-life of biologically active molecules by XTEN protein polymers

Journal of controlled release, 2016-10, Vol.240, p.52-66

2016

Volltextzugriff (PDF)

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

Nature biotechnology, 2009-12, Vol.27 (12), p.1186-1190

2009

Volltextzugriff (PDF)

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model

PloS one, 2012-11, Vol.7 (11), p.e50630

2012

Volltextzugriff (PDF)

Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose

PloS one, 2010-04, Vol.5 (4), p.e10175

2010

Volltextzugriff (PDF)

613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A368-A369

2020

Volltextzugriff (PDF)

Rapid Evolution of Novel Traits in Microorganisms

Applied and Environmental Microbiology, 2001-08, Vol.67 (8), p.3645-3649

2001

Volltextzugriff (PDF)

A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy

Molecular cancer therapeutics, 2005-11, Vol.4 (11), p.1791-1800

2005

Volltextzugriff (PDF)

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One. 2012; 7(11): e50630

PloS one, 2013, Vol.8 (6)

2013

Volltextzugriff (PDF)

Generation of large libraries of random mutants in Bacillus subtilis by PCR-based plasmid multimerization

BioTechniques, 1997-08, Vol.23 (2), p.304-310

1997

Volltextzugriff (PDF)

Abstract 3376: HER2-XPAT and EGFR-XPAT: Pro-drug T-cell engagers (TCEs) engineered to address o n -target, o ff -tumor toxicity with potent efficacy in vitro and in vivo and large safety margins in NHP

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3376-3376

2020

Volltextzugriff (PDF)

Abstract 1824: HER2-XPAT, a novel protease-activatable T-cell engager (TCE) with potent T-cell activation and efficacy in solid tumors and large safety margins in non-human primate (NHP)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1824-1824

2021

Volltextzugriff (PDF)

Abstract PS17-11: Her2-xpat, a novel protease-activatable prodrug t-cell engager (tce), exhibits potent t-cell activation and efficacy in her2 tumors, yielding large predicted safety margins based on non-human primate (nhp)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS17-11-PS17-11

2021

Volltextzugriff (PDF)

Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P193-P193

2021

Volltextzugriff (PDF)

Platelet-Targeted rFVIIa-Xten Improves Thrombin Generation and Fibrin Formation Compared to Recombinant FVIIa

Blood, 2015-12, Vol.126 (23), p.2269-2269

2015

Volltextzugriff (PDF)

Evaluation of Recombinant Fixfc-Xten Bleeding Efficacy in Hemophilia-B Mouse Models

Blood, 2016-12, Vol.128 (22), p.3757-3757

2016

Volltextzugriff (PDF)

Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility

Bioconjugate chemistry, 2014-07, Vol.25 (7), p.1351-1359

2014

Volltextzugriff (PDF)

Willem 'Pim' Stemmer 1957–2013

Nature biotechnology, 2013-07, Vol.31 (7), p.584-584

2013

Volltextzugriff (PDF)

Willem 'Pim' Stemmer 1957-2013: a truly original thinker and pioneering entrepreneur

Nature biotechnology, 2013-07, Vol.31 (7), p.584

2013

Volltextzugriff (PDF)

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

Journal of pharmaceutical sciences, 2012-08, Vol.101 (8), p.2744-2754

2012

Volltextzugriff (PDF)

Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer

Protein engineering, design and selection, 2013-11, Vol.26 (11), p.743-753

2013

Volltextzugriff (PDF)

Direct transformation of site-saturation libraries in Bacillus subtilis

BioTechniques, 2003-12, Vol.35 (6), p.1134-1140

2003

Volltextzugriff (PDF)

Identification of Active Coagulation Factor IX Variants with Insertion or Fusion of Unstructured Polypeptide Xten

Blood, 2015-12, Vol.126 (23), p.2280-2280

2015

Volltextzugriff (PDF)

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Nature cancer, 2023-04, Vol.4 (4), p.485-501

2023

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(75)
Tagungsberichte
(1)

Sprache

Englisch
(73)
Deutsch
(3)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Extension of in vivo half-life of biologically active molecules by XTEN protein polymers

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model

Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose

613 HER2-XPAT, a novel protease-activatable prodrug T cell engager (TCE), with potent T-cell activation and efficacy in solid tumors and large predicted safety margins in non-human primate (NHP)

Rapid Evolution of Novel Traits in Microorganisms

A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One. 2012; 7(11): e50630

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Generation of large libraries of random mutants in Bacillus subtilis by PCR-based plasmid multimerization

Abstract 3376: HER2-XPAT and EGFR-XPAT: Pro-drug T-cell engagers (TCEs) engineered to address o n -target, o ff -tumor toxicity with potent efficacy in vitro and in vivo and large safety margins in NHP

Abstract 1824: HER2-XPAT, a novel protease-activatable T-cell engager (TCE) with potent T-cell activation and efficacy in solid tumors and large safety margins in non-human primate (NHP)

Abstract PS17-11: Her2-xpat, a novel protease-activatable prodrug t-cell engager (tce), exhibits potent t-cell activation and efficacy in her2 tumors, yielding large predicted safety margins based on non-human primate (nhp)

A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)

Platelet-Targeted rFVIIa-Xten Improves Thrombin Generation and Fibrin Formation Compared to Recombinant FVIIa

Evaluation of Recombinant Fixfc-Xten Bleeding Efficacy in Hemophilia-B Mouse Models

Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility

Willem 'Pim' Stemmer 1957–2013

Willem 'Pim' Stemmer 1957-2013: a truly original thinker and pioneering entrepreneur

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer

Direct transformation of site-saturation libraries in Bacillus subtilis

Identification of Active Coagulation Factor IX Variants with Insertion or Fusion of Unstructured Polypeptide Xten

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Suchergebnisse filtern